Penn Center for Myeloproliferative Neoplasms

Saar I Gill

faculty photo

Saar I Gill

Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-4015
Lab: (215) 573-4015
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Blood and Marrow Transplantation
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Lymphoproliferative Neoplasms
Bone Marrow Failure

Description of Research Expertise

Tumor Immunology
Chimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry

Selected Publications

Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discov 12: 2372-2391, Oct 2022.

Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV.: Nomenclature for Cellular and Genetic Therapies: A Need for Standardization. Transplant Cell Ther Sep 2022.

Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT.: Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clin Cancer Res 28: 3804-3813, Sep 2022.

Saygin C, Roloff GW, Hahn CN, Chhetri R, Gill SI, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop MR, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown AL, Scott HS, Hiwase DK, Godley LA.: Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv Aug 2022.

Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW.: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6: 3997-4005, Jul 2022.

Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N.: Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat Commun 13: 3367, Jun 2022.

Tandel JV, Gill SI.: Epigenetic engineering empowers T cells. Blood 139: 2091-2092, Apr 2022.

Gill SI, Vides V, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL.: Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Adv Mar 2022.

AlJanahi AA, Lazzarotto CR, Chen S, Shin TH, Cordes S, Fan X, Jabara I, Zhou Y, Young DJ, Lee BC, Yu KR, Li Y, Toms B, Tunc I, Hong SG, Truitt LL, Klermund J, Andrieux G, Kim MY, Cathomen T, Gill S, Tsai SQ, Dunbar CE.: Prediction and validation of hematopoietic stem and progenitor cell off-target editing in transplanted rhesus macaques. Mol Ther 30: 209-222, Jan 2022.

Hatch RV, Freyer CW, Carulli A, Redline G, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz KW, Stadtmauer EA, Loren AW.: Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. J Oncol Pharm Pract 2022.

back to top
Last updated: 10/30/2022
The Trustees of the University of Pennsylvania

The Penn Difference

  • Individualized Treatment Plan
  • Expert Treatment Team Knowledgeable in Myeloproliferative Disorders
  • State-of-the-Art Personalized Diagnostic Testing
  • Access to Newest Therapies Through Clinical Trials
  • Comprehensive Bone Marrow Transplantation Service
  • Integrated Care by a Multidisciplinary Treatment Team

Make an Appointment

New Patients:
Abramson Cancer Center
Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
Philadelphia, PA 19104
Phone: 215-615-5858 option 2
Fax: 215-615-5889

Current Patients:
Contact your doctor directly

For General Inquiries:
Call the Myeloproliferative Neoplasms Program at  215-614-1847